术前化疗可提高患Askin肿瘤儿童的生存率。
Preresection chemotherapy improves survival for children with Askin tumors.
作者信息
Sawin R S, Conrad E U, Park J R, Waldhausen J H
机构信息
Department of Surgery, Children's Hospital and Medical Center, University of Washington School of Medicine, Seattle, USA.
出版信息
Arch Surg. 1996 Aug;131(8):877-80. doi: 10.1001/archsurg.1996.01430200087015.
OBJECTIVE
To test whether patients with Askin tumor treated with aggressive neoadjuvant chemotherapy have a better clinical outcome.
DESIGN
Retrospective case series.
SETTING
Pediatric referral center.
PATIENTS
All children diagnosed with malignant small-cell tumors of the chest wall (Askin tumor) and treated from 1975 to September 1987 (phase 1, n = 6) and from September 1987 to the present (phase 2, n = 9).
MAIN OUTCOME MEASURES
Survival as a function of extent of disease and response to therapy as measured by tumor volume, survival, and recurrence.
RESULTS
All phase 2 patients had significant reduction of tumor volume and improved survival by Kaplan-Meier estimates compared with phase 1 patients. No phase 1 patients are still alive.
CONCLUSION
Patients with Askin tumor treated with aggressive preresection chemotherapy have smaller tumors to resect and improved survival.
目的
测试接受积极新辅助化疗的Askin肿瘤患者是否有更好的临床结局。
设计
回顾性病例系列研究。
地点
儿科转诊中心。
患者
所有1975年至1987年9月（第1阶段，n = 6）以及1987年9月至目前（第2阶段，n = 9）被诊断为胸壁恶性小细胞肿瘤（Askin肿瘤）并接受治疗的儿童。
主要观察指标
根据疾病范围和通过肿瘤体积、生存率及复发情况衡量的治疗反应得出的生存率。
结果
与第1阶段患者相比，所有第2阶段患者的肿瘤体积均显著减小，根据Kaplan-Meier估计生存率有所提高。第1阶段患者无存活者。
结论
接受积极术前化疗的Askin肿瘤患者需要切除的肿瘤较小，生存率提高。
Zotero 插件